Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.
Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
Ozempic and similar drugs for Type 2 diabetes and weight loss are in such ... Novo Nordisk and Eli Lilly are moving to end ...
Amgen also says its drug is designed with a long half-life, which enables longer ... Lilly’s Zepbound. But it’s worth noting that Lilly is also developing a next-generation weight loss drug ...